Phase 2 study of concurrent radiotherapy and temozolomide followed by temozolomide and lomustine in the treatment of children with high-grade glioma: a report of the Children's Oncology Group ACNS0423 study

Phase 2 study of concurrent radiotherapy and temozolomide followed by temozolomide and lomustine in the treatment of children with high-grade glioma: a report of the Children's Oncology Group ACNS0423 study

akacki, R, (2016) Neuro-Oncology,  (Link to Abstract)


Authors report results of COG ACNS0423, a phase 2 study evaluating efficacy of temozolomide and lomustine combination in maintenance therapy in childhood high-grade glioma. Results are retrospectively compared to previous study ACNS0126 where temozolomide only was used. In the current study, it was shown that combination temozolomide and lomustine in 108 patients improves 3-year EFS to 22% (compared to 11% in ACNS0126). On the other hand this treatment was accompanied by significant hematological toxicity requiring dose reductions in 68% patients.


* The addition of lomustine to temozolomide as adjuvant therapy in ACNS0423 was associated with significantly improved outcome compared with the preceding COG ACNS0126 HGG study in which participants received temozolomide alone.